325 related articles for article (PubMed ID: 30414064)
1. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies.
Nash P; Coates LC; Fleischmann R; Papp KA; Gomez-Reino JJ; Kanik KS; Wang C; Wu J; Menon S; Hendrikx T; Ports WC
Rheumatol Ther; 2018 Dec; 5(2):567-582. PubMed ID: 30414064
[TBL] [Abstract][Full Text] [Related]
2. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials.
Kivitz AJ; FitzGerald O; Nash P; Pang S; Azevedo VF; Wang C; Takiya L
Clin Rheumatol; 2022 Feb; 41(2):499-511. PubMed ID: 34510295
[TBL] [Abstract][Full Text] [Related]
4. Tofacitinib in psoriatic arthritis patients: skin signs and symptoms and health-related quality of life from two randomized phase 3 studies.
Merola JF; Papp KA; Nash P; Gratacós J; Boehncke WH; Thaçi D; Graham D; Hsu MA; Wang C; Wu J; Young P
J Eur Acad Dermatol Venereol; 2020 Dec; 34(12):2809-2820. PubMed ID: 32271970
[TBL] [Abstract][Full Text] [Related]
5. Network Meta-Analysis of Tofacitinib, Biologic Disease-Modifying Antirheumatic Drugs, and Apremilast for the Treatment of Psoriatic Arthritis.
Gladman DD; Orbai AM; Gomez-Reino J; Chang-Douglass S; Leoncini E; Burton HE; Kanik KS; Romero AB; Cappelleri JC; Hsu MA
Curr Ther Res Clin Exp; 2020; 93():100601. PubMed ID: 32983284
[TBL] [Abstract][Full Text] [Related]
6. Safety and Efficacy of Tofacitinib in Patients with Active Psoriatic Arthritis: Interim Analysis of OPAL Balance, an Open-Label, Long-Term Extension Study.
Nash P; Coates LC; Kivitz AJ; Mease PJ; Gladman DD; Covarrubias-Cobos JA; FitzGerald O; Fleishaker D; Wang C; Wu J; Hsu MA; Menon S; Fallon L; Romero AB; Kanik KS
Rheumatol Ther; 2020 Sep; 7(3):553-580. PubMed ID: 32506317
[TBL] [Abstract][Full Text] [Related]
7. Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Mease P; Hall S; FitzGerald O; van der Heijde D; Merola JF; Avila-Zapata F; Cieślak D; Graham D; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1537-1550. PubMed ID: 29045212
[TBL] [Abstract][Full Text] [Related]
8. Tofacitinib in Patients With Psoriatic Arthritis and Metabolic Syndrome: A Post hoc Analysis of Phase 3 Studies.
Ritchlin CT; Giles JT; Ogdie A; Gomez-Reino JJ; Helliwell P; Young P; Wang C; Wu J; Romero AB; Woolcott J; Stockert L
ACR Open Rheumatol; 2020 Oct; 2(10):543-554. PubMed ID: 32910531
[TBL] [Abstract][Full Text] [Related]
9. Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo.
Gladman DD; Coates LC; Wu J; Fallon L; Bacci ED; Cappelleri JC; Bushmakin AG; Helliwell PS
Arthritis Res Ther; 2022 Feb; 24(1):40. PubMed ID: 35139908
[TBL] [Abstract][Full Text] [Related]
10. Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Chen L; Kudlacz E; Wu J; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000808. PubMed ID: 30713722
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of tofacitinib on enthesitis in patients with active psoriatic arthritis: analysis of pooled data from two phase 3 studies.
Mease PJ; Orbai AM; FitzGerald O; Bedaiwi M; Dona L Fleishaker ; Mundayat R; Young P; Helliwell PS
Arthritis Res Ther; 2023 Aug; 25(1):153. PubMed ID: 37608391
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of tofacitinib in Chinese patients with active psoriatic arthritis: a phase 3, randomised, double-blind, placebo-controlled study.
Leng X; Lin W; Liu S; Kanik K; Wang C; Wan W; Jiang Z; Liu Y; Liu S; Zhang Z; Zhang Z; Xu J; Tan W; Hu J; Li J; Liu J; Gunay LM; Dina O; Kinch C; Zeng X
RMD Open; 2023 Jan; 9(1):. PubMed ID: 36720560
[TBL] [Abstract][Full Text] [Related]
13. Effect of tofacitinib on dactylitis and patient-reported outcomes in patients with active psoriatic arthritis: post-hoc analysis of phase III studies.
Orbai AM; Mease PJ; Helliwell PS; FitzGerald O; Fleishaker DL; Mundayat R; Young P
BMC Rheumatol; 2022 Sep; 6(1):68. PubMed ID: 36045453
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden-a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs.
Strand V; de Vlam K; Covarrubias-Cobos JA; Mease PJ; Gladman DD; Graham D; Wang C; Cappelleri JC; Hendrikx T; Hsu MA
RMD Open; 2019; 5(1):e000806. PubMed ID: 30713721
[TBL] [Abstract][Full Text] [Related]
15. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension.
Eder L; Gladman DD; Mease P; Pollock RA; Luna R; Aydin SZ; Ogdie A; Polachek A; Gruben D; Cadatal MJ; Kinch C; Strand V
RMD Open; 2023 Mar; 9(1):. PubMed ID: 36958766
[TBL] [Abstract][Full Text] [Related]
16. Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Gladman D; Rigby W; Azevedo VF; Behrens F; Blanco R; Kaszuba A; Kudlacz E; Wang C; Menon S; Hendrikx T; Kanik KS
N Engl J Med; 2017 Oct; 377(16):1525-1536. PubMed ID: 29045207
[TBL] [Abstract][Full Text] [Related]
17. Tofacitinib as monotherapy following methotrexate withdrawal in patients with psoriatic arthritis previously treated with open-label tofacitinib plus methotrexate: a randomised, placebo-controlled substudy of OPAL Balance.
Nash P; Mease PJ; Fleishaker D; Wu J; Coates LC; Behrens F; Gladman DD; Kivitz AJ; Wei JC; Shirinsky I; Menon S; Romero AB; Fallon L; Hsu MA; Wang C; Kanik KS
Lancet Rheumatol; 2021 Jan; 3(1):e28-e39. PubMed ID: 38273637
[TBL] [Abstract][Full Text] [Related]
18. Costs and Health Outcomes Associated with Tofacitinib Treatment for Active Psoriatic Arthritis in the United States.
Bungey G; Chang-Douglass S; Hsu MA; Cappelleri JC; Young P; Woolcott J
J Manag Care Spec Pharm; 2020 Aug; 26(8):1027-1038. PubMed ID: 32308099
[TBL] [Abstract][Full Text] [Related]
19. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of Latin American patients with rheumatoid arthritis: Pooled efficacy and safety analyses of Phase 3 and long-term extension studies.
Radominski SC; Cardiel MH; Citera G; Goecke A; Jaller JJ; Lomonte ABV; Miranda P; Velez P; Xibillé D; Kwok K; Rojo R; García EG
Reumatol Clin; 2017; 13(4):201-209. PubMed ID: 27317492
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population.
Hall S; Nash P; Rischmueller M; Bossingham D; Bird P; Cook N; Witcombe D; Soma K; Kwok K; Thirunavukkarasu K
Rheumatol Ther; 2018 Dec; 5(2):383-401. PubMed ID: 29949132
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]